Drug
Icp 332
Icp 332: highest development phase Phase 3, developed by InnoCare Pharma. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- InnoCare Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| ICP-332 Tablets NCT06775860 | Phase 3 | Atopic Dermatitis |
| ICP-332 Tablets NCT07378527 | Phase 2/3 | Chronic Spontaneous Urticaria (CSU) |
| ICP-332 Tablets NCT07047612 | Phase 2/3 | Non Segmental Vitiligo |
| ICP-332 NCT05702268 | Phase 2 | Moderate to Severe Atopic Dermatitis |
| ICP-332 Tablets NCT06530966 | Phase 1 | Healthy Subjects |
Latest
No recent events.
Follow Icp 332 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.